NASDAQ:AMAG - AMAG Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$23.00 -0.80 (-3.36 %)
(As of 06/19/2018 06:37 AM ET)
Previous Close$23.80
Today's Range$22.95 - $23.75
52-Week Range$11.93 - $25.63
Volume975,575 shs
Average Volume695,419 shs
Market Capitalization$816.97 million
P/E Ratio-4.03
Dividend YieldN/A
AMAG Pharmaceuticals logoAMAG Pharmaceuticals, Inc., a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families. In addition, it has an option agreement with Velo Bio LLC to acquire the rights to digoxin immune fab, a polyclonal antibody, which is in Phase IIb/IIIa trial for the treatment of severe preeclampsia in pregnant women. The company sells Feraheme to authorized wholesalers and specialty distributors. It has a license agreement with Palatin Technologies, Inc. to research, develop, and commercialize Bremelanotide, an investigational product for the treatment of hypoactive sexual desire disorder (HSDD) in pre-menopausal women, as well as with Endoceutics, Inc. to develop and commercialize pharmaceutical products with dehydroepiandrosterone; and development and license agreement with Antares Pharma, Inc. to develop, use, sell, offer for sale, and import and export the Makena auto-injector. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Receive AMAG News and Ratings via Email

Sign-up to receive the latest news and ratings for AMAG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity Ratio0.97
Current Ratio1.57
Quick Ratio1.48


Trailing P/E Ratio-4.03
Forward P/E Ratio-6.73
P/E GrowthN/A

Sales & Book Value

Annual Sales$609.95 million
Price / Sales1.29
Cash FlowN/A
Price / CashN/A
Book Value$22.34 per share
Price / Book1.03


EPS (Most Recent Fiscal Year)($5.71)
Net Income$-199,220,000.00
Net Margins-35.17%
Return on Equity-1.15%
Return on Assets-0.47%


Outstanding Shares34,330,000

AMAG Pharmaceuticals (NASDAQ:AMAG) Frequently Asked Questions

What is AMAG Pharmaceuticals' stock symbol?

AMAG Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMAG."

How were AMAG Pharmaceuticals' earnings last quarter?

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced its earnings results on Thursday, May, 3rd. The specialty pharmaceutical company reported ($1.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by $1.10. The specialty pharmaceutical company earned $146.40 million during the quarter, compared to the consensus estimate of $149.13 million. AMAG Pharmaceuticals had a negative return on equity of 1.15% and a negative net margin of 35.17%. The firm's revenue was up 4.9% on a year-over-year basis. During the same period in the prior year, the company posted ($1.06) EPS. View AMAG Pharmaceuticals' Earnings History.

When is AMAG Pharmaceuticals' next earnings date?

AMAG Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for AMAG Pharmaceuticals.

What price target have analysts set for AMAG?

10 analysts have issued 12-month price targets for AMAG Pharmaceuticals' stock. Their predictions range from $17.00 to $30.00. On average, they anticipate AMAG Pharmaceuticals' share price to reach $22.8650 in the next year. View Analyst Ratings for AMAG Pharmaceuticals.

What are Wall Street analysts saying about AMAG Pharmaceuticals stock?

Here are some recent quotes from research analysts about AMAG Pharmaceuticals stock:
  • 1. Cantor Fitzgerald analysts commented, "Makena autoinjector moving to launch pad. On today’s call, management commented that the autoinjector would be launched by the end of March. Pre- launch activities include the critical element of providing patient access to the drug. We believe it possible that the switch to the autoinjector could be facilitated through modulating the Makena vial (IM administration) inventory." (2/27/2018)
  • 2. According to Zacks Investment Research, "AMAG reported earnings of $1.57 in the third quarter of 2017 as against the Zacks Consensus Estimate of a loss. However, the company missed the same on revenues. AMAG lowered its total revenue guidance for 2017. Furthermore, the termination of the licensing agreement with Takeda for Feraheme in ex-U.S. territories was a major setback for the company. So far this year, AMAG’s shares have underperformed the industry.  Nevertheless, the company  is working towards label expansion of Feraheme, and potential approval and launch of the Makena subcutaneous auto-injector (SQ) AMAG also remains focused on expanding Makena’s label further in a bid to increase its market share." (11/8/2017)

Who are some of AMAG Pharmaceuticals' key competitors?

Who are AMAG Pharmaceuticals' key executives?

AMAG Pharmaceuticals' management team includes the folowing people:
  • Dr. William K. Heiden, CEO & Director (Age 58)
  • Mr. Edward H. Myles MBA, Exec. VP & CFO (Age 46)
  • Mr. Joseph D. Vittiglio Esq., Exec. VP of Quality, Gen. Counsel & Sec. (Age 46)
  • Dr. Julie Krop M.D., Exec. VP & Chief Medical Officer (Age 52)
  • Mr. Nicholas Grund, Exec. VP & Chief Commercial Officer (Age 48)

Has AMAG Pharmaceuticals been receiving favorable news coverage?

Headlines about AMAG stock have trended somewhat positive on Tuesday, Accern reports. The research group ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AMAG Pharmaceuticals earned a media sentiment score of 0.10 on Accern's scale. They also assigned headlines about the specialty pharmaceutical company an impact score of 44.98 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are AMAG Pharmaceuticals' major shareholders?

AMAG Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Palo Alto Investors LP (9.73%), Dimensional Fund Advisors LP (3.33%), Northern Trust Corp (1.34%), Schwab Charles Investment Management Inc. (1.09%), Principal Financial Group Inc. (0.78%) and Principal Financial Group Inc. (0.78%). Company insiders that own AMAG Pharmaceuticals stock include Joseph Vittiglio, Julie Krop and William K Heiden. View Institutional Ownership Trends for AMAG Pharmaceuticals.

Which institutional investors are selling AMAG Pharmaceuticals stock?

AMAG stock was sold by a variety of institutional investors in the last quarter, including Prudential Financial Inc., Palo Alto Investors LP, Schwab Charles Investment Management Inc., Highland Capital Management LP, Systematic Financial Management LP, Hikari Power Ltd, Guggenheim Capital LLC and Alambic Investment Management L.P.. Company insiders that have sold AMAG Pharmaceuticals company stock in the last year include Joseph Vittiglio, Julie Krop and William K Heiden. View Insider Buying and Selling for AMAG Pharmaceuticals.

Which institutional investors are buying AMAG Pharmaceuticals stock?

AMAG stock was acquired by a variety of institutional investors in the last quarter, including Foundry Partners LLC, Hourglass Capital LLC, Piermont Capital Management Inc., ClariVest Asset Management LLC, Balter Liquid Alternatives LLC, LPL Financial LLC, Dupont Capital Management Corp and Voce Capital Management LLC. View Insider Buying and Selling for AMAG Pharmaceuticals.

How do I buy shares of AMAG Pharmaceuticals?

Shares of AMAG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AMAG Pharmaceuticals' stock price today?

One share of AMAG stock can currently be purchased for approximately $23.00.

How big of a company is AMAG Pharmaceuticals?

AMAG Pharmaceuticals has a market capitalization of $816.97 million and generates $609.95 million in revenue each year. The specialty pharmaceutical company earns $-199,220,000.00 in net income (profit) each year or ($5.71) on an earnings per share basis. AMAG Pharmaceuticals employs 762 workers across the globe.

How can I contact AMAG Pharmaceuticals?

AMAG Pharmaceuticals' mailing address is 1100 WINTER STREET, WALTHAM MA, 02451. The specialty pharmaceutical company can be reached via phone at 617-498-3300 or via email at [email protected]

MarketBeat Community Rating for AMAG Pharmaceuticals (AMAG)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  294 (Vote Outperform)
Underperform Votes:  365 (Vote Underperform)
Total Votes:  659
MarketBeat's community ratings are surveys of what our community members think about AMAG Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMAG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMAG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/19/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.